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Stratified Medicine in Psychiatry: What Service Users, Carers and 
the Public Think 
Introduction  
Stratified medicine has been described as the ‘next big thing’ in medical research, with 
millions of pounds in funding from government bodies like the Medical Research Council and 
Technology Strategy Board, and charities like Cancer Research UK. At heart, it’s a simple 
idea; it means treating conditions based on tests which determine the likely treatment 
response, both its success and the side effects. These tests might be genetic (as in modern 
cancer treatment) involve imaging studies (as proposed in psychiatry) or be based on blood 
tests for biomarkers.  
There are two reasons stratified medicine may be important in psychiatry and more 
specifically for the treatment of people diagnosed with psychosis. First, antipsychotic 
medication currently is very much a matter of trial and error. Several medicines may be tried 
before an appropriate one is found and some service users never receive adequate 
treatment. What’s more, these medications frequently provoke unwanted effects which some 
service users can experience as worse than the diagnosed illness. Secondly, all anti-
psychotics currently available target one neurochemical system – the dopamine system. But 
researchers and clinicians now hypothesise that for some people with a diagnosis of 
psychosis dopamine pathways are not disturbed and a different neurochemical system, the 
glutamate pathway, is implicated. If this were so, it would explain why dopaminergic drugs 
do not work for everyone and would open the possibility of developing medications which 
specifically target the glutamate system. For this to be successful we need to develop a 
method to tell which patients are in each group. 
While this might sound like a simple case of research improving medical outcomes there are 
inevitable wrinkles. The research which aims to identify the markers of likely treatment 
response will involve medical data sharing on a massive scale, with serious questions being 
asked about the readiness of the UK healthcare system to manage data securely and 
ethically. Once techniques are developed there will be inevitable changes to the experience 
of individual patients. To introduce stratified medicine in psychiatry will mean that patients 
and service users will need to undergo tests to identify biomedical markers which indicate 
which drug they should take. Some of these tests are quite simple – for example, needle 
aspirations or check swabs – but others are much more invasive – for example, various 
forms of body or brain imaging which in turn can involve intravenous drips and chemical 
contrast agents and last several hours. It is important to find out how far patients and service 
users are willing to go to find a biomarker that could indicate which medication is appropriate 
for them. Further issues concern confidentiality and, in terms specifically of genetic tests, the 
possibility of data sharing. Finally, not all psychiatric service users believe that their 
problems are of biomedical origin; an assumption which underlies investment in this type of 
research.  
Two recent research projects have explored these issues with the public, service users and 
carers. The Service User Research Enterprise (SURE) at King’s College London aims to put 
the service user voice at the heart of mental health research. As preparation for clinical work 
on the dopamine and glutamate system, SURE was asked to investigate patient, service 
user and carer views. Three service user focus groups were held in Manchester, London 
and Edinburgh (totalling 18 people) and one carer focus group in London, at which there 
were eight participants. Each group discussed current approaches to prescribing 
antipsychotic medication and views of stratified medicine as an alternative, and explored 
participants’ attitudes towards particular test types and willingness to join a hypothetical 
clinical trial.  
Concurrently, the Technology Strategy Board, one of the main funders of stratified medicine 
research in the UK, commissioned research consultancy OPM Group to carry out a dialogue 
programme with the public, patients and stakeholders to understand how they interpreted 
these potential shifts in the way healthcare is delivered. Over 6 months OPM involved 
around 180 people in deliberative workshops where they learnt about and debated the 
potential of stratified medicine.   
Findings 
Current practice and the potential for stratified medicine 
The principle advantage of a stratified approach to treatment is that it eliminates the need to 
try one treatment after another to find one that works. For both the public and psychiatric 
service users the value of this was recognised, although with different degrees of emphasis. 
The public saw an opportunity for more efficient treatment; less inconvenient trips to the GP 
for different rounds of treatment; an end to waiting months between each hospital 
appointment. For service users and their carers the same principle applied to a greater 
degree:  
What got me was all the mucking about with the different 
antipsychotics, d'you know what I mean? I mean it took 
them a long time.... about ten years to find the right one for 
me?... Ten years to find, to put me on that (Service User) 
With my daughter it took seven years of trying different 
medication... it has taken a long time. It’s been, she’s been 
under psychiatric care for at least sixteen years (Carer) 
The prevalence of side effects was another motivator for public participants with experience 
of ill health to support stratified approaches; they commonly reported complex patterns of 
symptoms, side effects and co-morbidities. Some participants with a chronic physical 
condition described how the side effects could sometimes be as bad as the illness itself. 
Similarly among services users most participants expressed negative views on their 
experiences with medication. Discussions were dense with talk of never finding a drug 
without very debilitating side effects.  
 
It seems that all the drugs seem to be hit and miss.  None of 
them seem to work.  In fact I find my son tends to take the 
drug and then after a while he gets immune to it and then 
the old symptoms come back... and the drugs completely 
knock him out. ...any other sort of medication if you used 
the same sort of drug effects, people would be horrified. 
(Carer) 
 
Some people eventually found a helpful medication but the experience left others with the 
view that medication in general was to be avoided. These participants were sometimes 
cynical about the positive effects of medication in general, believing that they were not 
measurable and were outweighed by side effects: 
I mentioned about the negative side effects. I would like 
them to be explained to me - what sort of positive effects I 
could expect from this treatment and what I should be 
looking out for. It’s all very well participating taking the 
medications, but if you don’t know what to look for in terms 
of some improvement, how can you assess at least if it was 
successful? (Service User) 
This scepticism about the prevailing focus on biomedical causes of mental health presents a 
challenge for stratified medicine which takes the biomedical model as its starting point. As 
one services user advocated in the focus groups there is support for consideration of non-
biomedical causes and, consequently, treatment, of psychosis.  
But it seems to be all the same route of the sort of chemical 
imbalance. I did get invited to a lecture here actually, about 
the social origin of psychosis and I’ve heard [from] a lot of 
people with a diagnosis that it’s created sometimes by a 
traumatic experience. Is the manifestation of psychosis 
really to do with chemicals at all? (Service User) 
These concerns were echoed by some participants in the public dialogue, a number of 
whom felt that a stratified approach would lead healthcare professionals to focus on 
screening and testing protocols rather than a holistic assessment of the individual based on 
face to face interaction and knowledge of their situation. They were concerned for patients’ 
emotional needs to be taken into account alongside their medical needs.  
Rather than looking at the whole person you could end up 
looking at patients on the basis of a load of stats. (Dialogue 
participant, London public group) 
Acceptability of diagnostic tests 
Both the public dialogue and the service user/carer research asked participants to consider 
different types of diagnostic tests which could be used in a stratified system to identify likely 
treatment response. Understanding which tests are acceptable to patients should be 
important to those developing new approaches, as it will influence adherence and outcomes. 
At the outset, the researchers assumed that the physical invasiveness of tests would be the 
primary factor in determining their acceptability to patients. However, for all groups, the 
emergent picture was more complicated. Alongside physical invasiveness, there were 
concerns about subjective tests which involve some aspect of judgement from medical 
professionals and where the data collected were seen as personal. We can hypothesise two 
dimensions of concern about testing – one based on the physical experience of the test itself 
(what we typically call invasiveness). The other, which we might call intrusiveness, is 
based on the type of data collected and the potential for negative social consequences to 
arise from use and misuse of those data.  
Crucially, the carer group disagreed with the ‘hierarchy of invasiveness’ suggested by the 
academic researcher, in which neuropsychological tests would be the least invasive form of 
assessment. In fact, the carers believed these would be very invasive on two grounds: first, 
they would require sustained concentration over a long period of time which they felt their 
relatives would find difficult and tiring. Secondly, the carer group thought that ‘testing’ for 
attributes such as intelligence and cognitive functioning and would provoke anxiety and a 
feeling of being judged. Blood tests, conversely, they regarded as completely routine and 
without problems. For the service user groups the picture was not so straightforward: most 
thought blood tests acceptable, though some people described a fear of needles. . There 
was no clear view on neuropsychological tests, although concerns were voiced that puzzles 
could be “quite confusing and difficult” (Service user). 
For the public, lifestyle questionnaires and psychological interviews were particular 
examples of testing seen as intrusive, with participants describing these as more ‘personal’ 
than physical investigations. When probed on this, participants feared data being ‘used 
against you’ – perhaps indicating a lack of trust in the outcomes of subjective testing. When 
asked specifically about testing in a mental health context, even for physical tests, public 
participants were more concerned with confidentiality and data privacy than for physical 
conditions, with the exception of sexually transmitted diseases. A related tendency was for 
participants to be more concerned about genetic testing than other procedures; the public 
were very sensitive to the idea that genetic testing could reveal the potential for disease in 
the future, which would have immediate implications for insurance or employment. In both 
cases, the public were concerned not just with the procedure of the test but the type of data 
it produced suggesting that the acceptability of a testing protocol could decrease if the data 
produced were more ‘personal’. It seems that invasiveness alone is not a good predictor for 
the acceptability of a test. 
Among tests regarded as physically invasive, there was a sense of hierarchy from service 
user participants, which did accord with the researcher’s expectations. The longer and more 
complex the procedure, the more anxious participants were about taking part. Many 
participants, or their relatives, had actually already undergone MRI scans and at this point in 
the focus group discussions, there was varied willingness to have a similar MRS scan to 
establish neurochemical pathways and guide pharmacological intervention. 
But I wouldn’t mind having a brain scan, something like 
that, just to have a look at say the chemical reactions in the 
brain.  See I’ve had one of those scans before. (Service User) 
I’ve had all sorts of tests, I’ve been scanned in all different 
ways and I thought it’d be just like everything else, piece of 
cake.  That’s the only thing I’ve not been able to do.  They 
can stick needles in me all over, it doesn’t bother me in, in 
any way or they can operate on me, I’d rather see what’s 
going on.  I had a...knee replaced under an epidural and that 
was most interesting but could I go IN there! (Service User) 
Again participants talked about side effects, and in particular the way they might affect a 
service user’s ability to undergo a diagnostic test, regardless of their willingness to do so: 
Yes.  Also if you’ve had Clozapine and you put on a lot of 
weight. (Carer 1) Chances of you getting in the tube... (Carer 2) 
For more involved procedures such as PET scans (which involve drip infusions and chemical 
tracers and last for two to three hours) most participants viewed the tests as a “last resort” 
and “too much hard work”. Again the side effects of medication came up, with one carer 
suggesting her daughter: 
Certainly would need to go to the loo many times with the 
incontinence thing, but ... I don’t know that she would sit 
that long (Carer) 
Despite these concerns participants across the public and service user groups tended to 
take a pragmatic view that even unpleasant or undesirable tests could be acceptable if they 
might significantly improve the process of finding a successful treatment: 
It’s got to be better than going through changing tablets 
after tablets and them not working, you know what I mean 
and …. Your life, you know what I mean? These tests at the 
end of the day, you know at least you get an answer. (Service 
User) 
Participating in research 
Researchers hope that by looking at the treatment responses of a large enough number of 
patients, it will be possible to identify factors which predict that response. For example, 
Cancer Research UK is currently collecting tumour samples from up to 9000 cancer patients 
to produce a database for researchers to develop stratified and targeted treatments. The 
public dialogue found that people are generally agreeable to contributing to medical 
research – e.g. through trial participation or sharing medical records - strongly supporting the 
idea that they could contribute to improved outcomes for future patients.  
This was echoed in the service user research where many of the participants who had 
misgivings about MRS and PET in a clinical context nonetheless said they would be willing 
to participate in a trial. Some thought that this might help them personally, but most 
understood that it would not; that their involvement could instead benefit future patients and 
service users.  
But if [name] consented to it, if she knew what was going to 
go on and she consented to it...I think she would want to 
help because she would feel that she was helping other 
people by doing this (Carer) 
 
Despite this general support, the public, patients and carers all identified concerns about 
how this research might take place. For the public, most concerns were around the uses to 
which medical data are put; they had strong views on the rights of private companies to 
benefit commercially from research which they entered into from altruistic motives. For 
carers of service users, the most pressing concern was whether participating in any kind of 
trial would lead to deterioration in the condition of someone who was responding well to their 
current drug treatment. In one case, a carer held to this view even when one participant 
pointed out that for those who were stable on dopaminergic drugs, there would be no 
change in medication, merely a confirmation.  
Consent was another issue raised frequently: for example, public participants, when asked 
specifically about the participation of mental health service users in research, were primarily 
concerned with the capacity of patients to consent to take part in trials.  Among service 
users, an issue that preoccupied the participants was getting enough information: 
Yeah I would but it just depends on what kind of study it 
was.  If the doctor explained it all first. And if I didn’t feel as 
though I was ready for that study, I wouldn’t do it. (Service User) 
This was repeated in the public dialogue, where participants felt strongly that they would only 
take part in research where consent was truly informed. For the public, this meant 
understanding who would have access to the data collected, the security and governance 
arrangements, and the purpose of the research. Alongside the desire for research to be 
carried out in such a way as to minimise the possibility of abuse, participants also felt there 
was value in the consent process, as recognition of the active contribution of research 
participants:  
This has to be an informed choice; they have to have the 
respect to ask (Dialogue participant, Glasgow public group) 
Discussion  
These two research projects demonstrate that there is a good baseline of support for 
approaches which minimise trial and error by identifying biomarkers for likely treatment 
response. This is especially true in areas like psychiatry where drug side effects can be 
severe. However, this is not to say that there is universal agreement on a definition of 
stratified medicine, or on how this type of approach should develop, and fundamental 
questions remain about the wisdom of focusing entirely on biomedical causes. The more 
practical concerns of research participants about taking different types of diagnostic test 
(whether physically invasive or personally intrusive) also have implications for adherence. 
Suggestions from public and service users were to have other patients with experience of an 
intervention who could talk through the procedure. These issues apply equally to the 
research context, where success in clinical trials relies on the participation of a robust 
sample of patients.  
This type of social research early in the process of clinical research and policy development 
can offer valuable insights into the eventual consequences of the research/policy in 
question. In this case, SURE were also able to incorporate the service user voice – one 
which is still often marginalised. This ensures that new treatments are designed and 
evaluated from the ground up, with service users engaged throughout as informed 
collaborators rather than passive subjects.   
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